Nanobiotix H1 2026: Net Loss Widens to €34.3M, Cash at €110.9M After $100M Offering
NBTX has more than doubled off its 52-week low of $14.3.
Summary
Nanobiotix reported a €34.3M H1 2026 net loss and €110.9M cash position, with the May 2026 $100M offering providing runway beyond twelve months.
Key Events · Earnings and Guidance · NBTX
-
H1 2026 Net Loss of €34.3M
Net loss widened from €5.4M in H1 2025 to €34.3M in H1 2026, driven by €14.5M in interest costs on the royalty financing and EIB loan.
-
Cash Position of €110.9M
Cash and cash equivalents reached €110.9M as of June 30, 2026, up from €52.8M at year-end 2025, after the May 2026 global offering.
-
May 2026 Global Offering Completed
The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants for approximately $100M gross proceeds (€86.1M), with net proceeds of €80.1M.
-
Free Shares Granted to Executives
1,663,202 free shares (AGA 2026-P) were granted June 8, 2026, including 650,000 to Chairman Laurent Levy, with a two-year acquisition period ending June 8, 2028.
Analysis · NBTX · Life Sciences
The half-year report shows a net loss of €34.3M for H1 2026, up from €5.4M a year earlier, largely due to €14.5M in interest costs on royalty financing and an EIB loan. Cash stands at €110.9M following a $100M global offering completed in May 2026, which management says funds operations beyond the next twelve months. The filing also discloses 1.66M free shares granted to executives and employees, adding to the 6.38M potential dilutive instruments outstanding.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBTX was trading at $33.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $14.30 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.